Ilinpru Combi

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Ilinpru Combi (Metformin Hydrochloride, Linagliptin)

Q: What is Ilinpru Combi used for?

Ilinpru Combi is prescribed for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose by combining two complementary mechanisms: reduced hepatic glucose production and enhanced insulin secretion in response to meals.

Q: How does Metformin Hydrochloride and Linagliptin work?

Metformin Hydrochloride decreases liver glucose output and improves insulin sensitivity in muscle and fat tissue. Linagliptin blocks the enzyme DPP‑4, which raises levels of incretin hormones that stimulate insulin release and suppress glucagon when glucose is high, providing a synergistic glucose‑lowering effect.

Q: What is the usual dose of Ilinpru Combi?

The dose of Ilinpru Combi is individualized by the prescribing clinician based on the patient’s glycaemic targets, renal function, and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule for each patient.

Q: Is Ilinpru Combi safe in pregnancy or breastfeeding?

Use during pregnancy or lactation should only occur when the potential benefits outweigh the risks. Clinicians must evaluate maternal health, fetal safety data, and alternative therapies before prescribing this medication to pregnant or nursing women.

Q: How do I order Ilinpru Combi from GNH India?

To request Ilinpru Combi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Ilinpru Combi compare with other antidiabetic combos?

Ilinpru Combi combines metformin with linagliptin, offering a once‑daily oral regimen that addresses both insulin resistance and incretin deficiency. Compared with metformin‑sitagliptin combos, linagliptin has a lower risk of drug‑drug interactions because it is not primarily cleared by the kidneys, making it suitable for patients with moderate renal impairment.

Q: What are the storage and handling requirements for Ilinpru Combi?

Store Ilinpru Combi tablets at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Q: How is Ilinpru Combi administered?

Ilinpru Combi is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Q: What are the most serious risks associated with Ilinpru Combi?

The most serious adverse events include lactic acidosis (linked to metformin), pancreatitis, and severe hypoglycaemia, particularly when used with other glucose‑lowering agents. Prompt medical attention is required if patients experience sudden abdominal pain, unexplained weakness, or signs of low blood sugar.

Q: Who should not use Ilinpru Combi?

Ilinpru Combi is contraindicated in patients with severe renal impairment (eGFR < 30 ml/min/1.73 m²), known hypersensitivity to metformin, linagliptin, or any component of the formulation, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Metformin Hydrochloride and Linagliptin, the active ingredient in Ilinpru Combi, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH India supplies Ilinpru Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ilinpru Combi is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels. It helps achieve glycaemic control when used alone or in combination with other antidiabetic agents.

Type 2 diabetes mellitus: improves fasting plasma glucose and HbA1c levels.
Inadequate control on metformin alone: provides additional glucose‑lowering effect.
Combination therapy: allows simplified dosing with two complementary mechanisms.

How It Works

Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while linagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that stimulate glucose‑dependent insulin secretion and suppress glucagon release. The combined actions result in lower blood glucose concentrations.

Side Effects

Ilinpru Combi may cause a range of adverse reactions, most of which are mild and reversible. Patients should be aware of both common and serious possibilities.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Dizziness: transient episodes, especially on standing.
Upper respiratory tract symptoms: mild cough or sore throat.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal metabolic complication.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe hypoglycaemia: especially when combined with sulfonylureas or insulin.
Hypersensitivity reactions: rash, angioedema, or anaphylaxis.
Hepatic failure: signs of liver dysfunction.
Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating Ilinpru Combi, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal function assessment: confirm adequate eGFR and monitor periodically.
Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
Hepatic disease: use with caution and monitor liver enzymes.
Pregnancy and lactation: discuss potential risks and benefits with the prescriber.
Drug interactions: review concomitant medications for possible interactions.
Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Ilinpru Combi can interact with several medicines, requiring careful management to avoid adverse outcomes.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 ml/min/1.73 m²): contraindicated due to lactic acidosis risk.
Potent CYP3A4 inhibitors: may increase linagliptin exposure.
Duplicate DPP‑4 inhibition: avoid using with other DPP‑4 inhibitors.
High‑dose metformin plus sulfonylureas: heightened hypoglycaemia risk.
Iodinated contrast agents: may precipitate renal dysfunction.

Moderate Interactions (Monitor Closely)

Diuretics: monitor renal function and electrolytes.
ACE inhibitors or ARBs: watch for changes in renal function and potassium levels.
Alcohol consumption: may increase risk of lactic acidosis.

Frequently Asked Questions

Ilinpru Combi is prescribed for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose by combining two complementary mechanisms: reduced hepatic glucose production and enhanced insulin secretion in response to meals.

Metformin Hydrochloride decreases liver glucose output and improves insulin sensitivity in muscle and fat tissue. Linagliptin blocks the enzyme DPP‑4, which raises levels of incretin hormones that stimulate insulin release and suppress glucagon when glucose is high, providing a synergistic glucose‑lowering effect.

The dose of Ilinpru Combi is individualized by the prescribing clinician based on the patient’s glycaemic targets, renal function, and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule for each patient.

Use during pregnancy or lactation should only occur when the potential benefits outweigh the risks. Clinicians must evaluate maternal health, fetal safety data, and alternative therapies before prescribing this medication to pregnant or nursing women.

To request Ilinpru Combi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ilinpru Combi combines metformin with linagliptin, offering a once‑daily oral regimen that addresses both insulin resistance and incretin deficiency. Compared with metformin‑sitagliptin combos, linagliptin has a lower risk of drug‑drug interactions because it is not primarily cleared by the kidneys, making it suitable for patients with moderate renal impairment.

Store Ilinpru Combi tablets at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Ilinpru Combi is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious adverse events include lactic acidosis (linked to metformin), pancreatitis, and severe hypoglycaemia, particularly when used with other glucose‑lowering agents. Prompt medical attention is required if patients experience sudden abdominal pain, unexplained weakness, or signs of low blood sugar.

Ilinpru Combi is contraindicated in patients with severe renal impairment (eGFR < 30 ml/min/1.73 m²), known hypersensitivity to metformin, linagliptin, or any component of the formulation, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.